U.S. FDA Approves Abrysvo, Pfizer ’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

NEW YORK--(BUSINESS WIRE) August 21, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news